Ocugen, Inc. (BMV:OCGN)

Market Cap	7.66B +37.4%
Revenue (ttm)	80.49M -1.3%
Net Income	-1.29B
EPS	-4.18
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	326
Open	23.00
Previous Close	23.00
Day's Range	22.40 - 23.00
52-Week Range	18.40 - 45.50
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Ocugen

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 116
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: OCGN

Financial Performance

In 2025, Ocugen's revenue was $4.41 million, an increase of 8.83% compared to the previous year's $4.06 million. Losses were -$67.85 million, 25.5% more than in 2024.

Financial numbers in USD

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jul 21, 2026

Data Sources Report a data error